Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Fulcrum Therapeutics Q4 GAAP EPS $(0.40) Beats $(0.43) Estimate, Sales $871.00K Beat $460.00K Estimate; Cash Balance Of $236.2M Expected To Provide Cash Runway Into 2026

Author: Benzinga Newsdesk | February 27, 2024 08:08am

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 20 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $871.00 thousand which beat the analyst consensus estimate of $460.00 thousand by 89.35 percent. This is a 27.15 percent increase over sales of $685.00 thousand the same period last year.

Posted In: FULC